Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Nonclinical Safety of SHP 826 (BAX 826), a Next Generation Extended Half-Life Recombinant Factor VIII Product

Veronika Ehrlich, Peter Leidenmuehler, Barbara Dietrich, Gerald Hoebarth, Tanja Ruthsatz, Peter L. Turecek, PhD, Martin Wolfsegger, Cstat (RSS), Alfred Weber, Herbert Gritsch, Werner Hoellriegl, Marietta Turecek

Blood (2016) 128 (22): 4977.

https://doi.org/10.1182/blood.V128.22.4977.4977

Published: 2016

Journal Articles

Pharmacokinetics of BAX 826, a Polysialylated Full-Length rFVIII, in Hemophilia a Mice, Rats, and Cynomolgus Monkeys

Alexandra Schiviz, DVM, Gerald Hoebarth, Martin Wolfsegger, Paolo Rossato, Alfred Weber, Herbert Gritsch, Hanspeter Rottensteiner, PhD, Peter L. Turecek, PhD, Friedrich Scheiflinger, PhD, Werner Hoellriegl, DVM, Marietta Putz, MS

Blood (2015) 126 (23): 1073.

https://doi.org/10.1182/blood.V126.23.1073.1073

Published: 2015

Journal Articles

Recombinant VWF Promotes Platelet Adhesion Under Shear Stress Dependent on Its Multimer Size

Gerald Schrenk, PhD, Jutta Schreiner, Herbert Gritsch, Peter L Turecek, PhD, Michael Dockal, PhD, Friedrich Scheiflinger, PhD

Blood (2014) 124 (21): 1442.

https://doi.org/10.1182/blood.V124.21.1442.1442

Published: 2014

Journal Articles

Pharmacokinetics of Baxter’s Longer Acting rFVIII (BAX 855) in Factor VIII Ko Mice, Rats and Cynomolgus Monkeys

Gerald Hoebarth, DVM, Susan Kubik, BSc, Martin Wolfsegger, PhD, John-Philip Lawo, Alfred Weber, PhD, Herbert Gritsch, Werner Hoellriegl, Alexandra Schiviz, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch

Blood (2011) 118 (21): 4346.

https://doi.org/10.1182/blood.V118.21.4346.4346

Published: 2011

Journal Articles

Functional Characterization of BAX 855, a PEGylated Recombinant FVIII

Gerald Schrenk, PhD, Katalin Varadi, PhD, Herbert Gritsch, Hanspeter Rottensteiner, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD

Blood (2011) 118 (21): 4359.

https://doi.org/10.1182/blood.V118.21.4359.4359

Published: 2011

Journal Articles

2D-DIGE As a Tool to Analyze Lot-to-Lot Consistency of Complex Therapeutic Products Such As BAX 855, a PEGylated Recombinant FVIII

Hanspeter Rottensteiner, PhD, Christina Monetti, Herbert Gritsch, Alfred Weber, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD

Blood (2011) 118 (21): 4360.

https://doi.org/10.1182/blood.V118.21.4360.4360

Published: 2011

Journal Articles

In Vivo Cleavage of Recombinant VWF Upon Intravenous Administration in Preclinical and Clinical Settings

Katalin Varadi, PhD, Hanspeter Rottensteiner, PhD, Jutta Schreiner, Herbert Gritsch, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD

Blood (2011) 118 (21): 1222.

https://doi.org/10.1182/blood.V118.21.1222.1222

Published: 2011

Journal Articles

Toxico-Kinetics of Recombinant VWF In Non-Human Primates and Rabbits

Eva-Maria Muchitsch, PhD, Barbara Dietrich, PhD, Hanspeter Rottensteiner, PhD, Herbert Gritsch, Hartmut J. Ehrlich, MD, Peter Turecek, PhD, Hans Peter Schwarz, MD

Blood (2010) 116 (21): 1414.

https://doi.org/10.1182/blood.V116.21.1414.1414

Published: 2010

Journal Articles

Single Dose Pharmacokinetics of a Recombinant FVIIa In Factor VIII KO Mice, Rats, and Cynomolgus Monkeys

Gerald Hoebarth, PhD, Susan Kubik, PhD, Martin Wolfsegger, PhD, John-Philip Lawo, PhD, Alfred Weber, PhD, Herbert Gritsch, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch, PhD

Blood (2010) 116 (21): 4655.

https://doi.org/10.1182/blood.V116.21.4655.4655

Published: 2010

Journal Articles

Kinetics of Human VWF Cleavage by Human ADAMTS13: Comparison of Recombinant and Plasma-Derived VWF

Hanspeter Rottensteiner, PhD, Katalin Varadi, PhD, Susanne Vejda, PhD, Jutta Schreiner, Herbert Gritsch, Peter L. Turecek, PhD, Hartmut J Ehrlich, MD, Hans Peter Schwarz, MD

Blood (2008) 112 (11): 4092.

https://doi.org/10.1182/blood.V112.11.4092.4092

Published: 2008

Journal Articles

Effect of Human Recombinant VWF Administration on Plasma ADAMTS13 Activities in Non-Human Primates and Rabbits

Katalin Varadi, PhD, Hanspeter Rottensteiner, PhD, Eva M Muchitsch, PhD, Alfred Weber, PhD, Herbert Gritsch, Peter L. Turecek, PhD, Hartmut J Ehrlich, MD, Hans Peter Schwarz, MD

Blood (2008) 112 (11): 4105.

https://doi.org/10.1182/blood.V112.11.4105.4105

Published: 2008

Journal Articles

In Vitro and In Vivo Characterization of Full-Length rFVIII Modified with PEG Via Coupling to Primary Amino Groups.

Peter L. Turecek, PhD, Jürgen Siekmann, PhD, Herbert Gritsch, Katalin Váradi, PhD, Rafi-Uddin Ahmad, Eva-Maria Muchitsch, DVM, Hartmut Ehrlich, MD, Hans Peter Schwarz, MD

Blood (2007) 110 (11): 3147.

https://doi.org/10.1182/blood.V110.11.3147.3147

Published: 2007

Journal Articles

Species-Dependent Variability of ADAMTS-13 Mediated Proteolysis of Human Recombinant von Willebrand Factor.

Katalin Varadi, PhD, Hanspeter Rottensteiner, PhD, Peter L. Turecek, PhD, Jutta Schreiner, Herbert Gritsch, Bernhard Baumgartner, DVM, Eva-Maria Muchitsch, DVM, Hartmut Ehrlich, MD, Hans Peter Schwarz, MD

Blood (2007) 110 (11): 2139.

https://doi.org/10.1182/blood.V110.11.2139.2139

Published: 2007

Journal Articles

Modification of rVWF with Polysialic Acid: Biochemical and Functional Characterization in Mice with VWD.

Peter L. Turecek, PhD, Juergen Siekmann, PhD, Alfred Weber, PhD, Herbert Gritsch, PhD, Katalin Váradi, PhD, H. Peter Matthiessen, PhD, Eva-Maria Muchitsch, DVM, Bernhard Baumgartner, DVM, Hans Peter Schwarz, MD

Blood (2006) 108 (11): 1001.

https://doi.org/10.1182/blood.V108.11.1001.1001

Published: 2006

Journal Articles

PEG Modified rVWF Prolongs the Survival of Native rFVIII in Hemophilia A Knock-Out Mice.

Peter L. Turecek, PhD, Friedrich Scheiflinger, PhD, Herbert Gritsch, PhD, Bernhard Baumgartner, DVM, Katalin Váradi, PhD, H. Peter Matthiessen, PhD, Juergen Siekmann, PhD, Eva-Maria Muchitsch, DVM, Hans Peter Schwarz, MD

Blood (2006) 108 (11): 1002.

https://doi.org/10.1182/blood.V108.11.1002.1002

Published: 2006

Journal Articles

Biochemical and Functional Characterization of a Serum-Free rVWF Drug Candidate.

Peter L. Turecek, PhD, H. Peter Matthiessen, PhD, Artur Mitterer, PhD, Herbert Gritsch, PhD, Katalin Váradi, PhD, Barbara Plaimauer, PhD, Martin Purtscher, PhD, Wilfried Woehrer, PhD, Eva-Maria Muchitsch, DVM, Hans Peter Schwarz, MD

Blood (2006) 108 (11): 1017.

https://doi.org/10.1182/blood.V108.11.1017.1017

Published: 2006

Journal Articles

Biochemical and Functional Characterization of PEGylated rVWF.

Peter L. Turecek, PhD, Friedrich Scheiflinger, PhD, Juergen Siekmann, PhD, Katalin Váradi, PhD, H. Peter Matthiessen, PhD, Alfred Weber, PhD, Herbert Gritsch, PhD, Eva-Maria Muchitsch, DVM, Bernhard Baumgartner, DVM, Hans Peter Schwarz, MD

Blood (2006) 108 (11): 1021.

https://doi.org/10.1182/blood.V108.11.1021.1021

Published: 2006

Journal Articles

In Vivo Characterization of Recombinant von Willebrand Factor in Dogs With von Willebrand Disease

Peter L. Turecek, Herbert Gritsch, Ludwig Pichler, Wilfried Auer, Bernhard Fischer, Artur Mitterer, Wolfgang Mundt, Uwe Schlokat, Friedrich Dorner, Herm Jan M. Brinkman, Jan A. van Mourik, Hans Peter Schwarz

Blood (1997) 90 (9): 3555–3567.

https://doi.org/10.1182/blood.V90.9.3555

Published: 1997

NARROW

Nonclinical Safety of SHP 826 (BAX 826), a Next Generation Extended Half-Life Recombinant Factor VIII Product

Pharmacokinetics of BAX 826, a Polysialylated Full-Length rFVIII, in Hemophilia a Mice, Rats, and Cynomolgus Monkeys

Recombinant VWF Promotes Platelet Adhesion Under Shear Stress Dependent on Its Multimer Size

Pharmacokinetics of Baxter’s Longer Acting rFVIII (BAX 855) in Factor VIII Ko Mice, Rats and Cynomolgus Monkeys

Functional Characterization of BAX 855, a PEGylated Recombinant FVIII

2D-DIGE As a Tool to Analyze Lot-to-Lot Consistency of Complex Therapeutic Products Such As BAX 855, a PEGylated Recombinant FVIII

In Vivo Cleavage of Recombinant VWF Upon Intravenous Administration in Preclinical and Clinical Settings

Toxico-Kinetics of Recombinant VWF In Non-Human Primates and Rabbits

Single Dose Pharmacokinetics of a Recombinant FVIIa In Factor VIII KO Mice, Rats, and Cynomolgus Monkeys

Kinetics of Human VWF Cleavage by Human ADAMTS13: Comparison of Recombinant and Plasma-Derived VWF

Effect of Human Recombinant VWF Administration on Plasma ADAMTS13 Activities in Non-Human Primates and Rabbits

In Vitro and In Vivo Characterization of Full-Length rFVIII Modified with PEG Via Coupling to Primary Amino Groups.

Species-Dependent Variability of ADAMTS-13 Mediated Proteolysis of Human Recombinant von Willebrand Factor.

Modification of rVWF with Polysialic Acid: Biochemical and Functional Characterization in Mice with VWD.

PEG Modified rVWF Prolongs the Survival of Native rFVIII in Hemophilia A Knock-Out Mice.

Biochemical and Functional Characterization of a Serum-Free rVWF Drug Candidate.

Biochemical and Functional Characterization of PEGylated rVWF.

In Vivo Characterization of Recombinant von Willebrand Factor in Dogs With von Willebrand Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only